Stuth Eckehard A E, Berens Richard J, Staudt Susan R, Robertson Frederick A, Scott John P, Stucke Astrid G, Hoffman George M, Troshynski Todd J, Tweddell James S T, Zuperku Edward J
Department of Anesthesiology, Section of Pediatric Anesthesia, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI 53201, USA.
Paediatr Anaesth. 2011 Apr;21(4):441-53. doi: 10.1111/j.1460-9592.2011.03527.x. Epub 2011 Feb 10.
High-dose single-shot caudal morphine has been postulated to facilitate early extubation and to lower initial analgesic requirements after staged single-ventricle (SV) palliation.
With Institutional Review Board approval and written informed parental consent, 64 SV children aged 75-1667 days were randomized to pre-incisional caudal morphine-bupivacaine (100 μg·kg(-1) morphine (concentration 0.1%), mixed with 0.25% bupivacaine with 1 : 200,000 epinephrine, total 1 ml·kg(-1)) and postcardiopulmonary bypass (CPB) intravenous (IV) droperidol (75 μg·kg(-1)) ('active caudal group') or pre-incisional caudal saline (1 ml·kg(-1)) and post-CPB IV morphine (150 μg·kg(-1)) with droperidol (75 μg·kg(-1)) ('active IV group'). Assignment remained concealed from families and the care teams throughout the trial. Early extubation failure rates (primary or reintubation within 24 h), time to first postoperative rescue morphine analgesia, and 12-h postoperative morphine requirements were assessed for extubated patients.
Thirty-one (12 stage 2) SV patients received caudal morphine and 32 (15 stage 2) received IV morphine. Extubation failure rates were 6/31 (19%) for caudal and 5/32 (16%) for IV morphine. For successfully extubated patients (n = 54), active caudal treatment significantly delayed the need for postoperative rescue morphine in stage 3 patients (P = 0.02) but not in stage 2 patients (P = 0.189) (Kaplan-Meier survival analysis with LogRank test). The reduction in 12-h postoperative morphine requirements with active caudal treatment did not reach significance (P = 0.085) but morphine requirements were significantly higher for stage 2 compared with stage 3 patients (P < 0.001) (two-way anova in n = 50 extubated patients).
High-dose caudal morphine with bupivacaine delayed the need for rescue morphine analgesia in stage 3 patients. All stage 2 patients required early rescue morphine and had significantly higher postoperative 12-h morphine requirements than stage 3 patients. Early extubation is feasible for the majority of stage 2 and 3 SV patients regardless of analgesic regimen. The study was underpowered to assess differences in extubation failure rates.
大剂量单次骶管注射吗啡被认为有助于早期拔管,并降低单心室(SV)分期姑息治疗后的初始镇痛需求。
经机构审查委员会批准并获得家长书面知情同意后,将64名年龄在75至1667天的SV患儿随机分为两组,一组在切开前接受骶管注射吗啡-布比卡因(100μg·kg⁻¹吗啡(浓度0.1%),与含1:200,000肾上腺素的0.25%布比卡因混合,总量1ml·kg⁻¹)及体外循环(CPB)后静脉注射(IV)氟哌利多(75μg·kg⁻¹)(“骶管活性组”),另一组在切开前接受骶管注射生理盐水(1ml·kg⁻¹)及CPB后静脉注射吗啡(150μg·kg⁻¹)和氟哌利多(75μg·kg⁻¹)(“静脉活性组”)。在整个试验过程中,家庭和护理团队对分组情况均不知情。对已拔管的患者评估早期拔管失败率(24小时内初次或再次插管)、术后首次需要急救吗啡镇痛的时间以及术后12小时的吗啡需求量。
31名(12名2期)SV患者接受了骶管注射吗啡,32名(15名2期)接受了静脉注射吗啡。骶管注射组的拔管失败率为6/31(19%),静脉注射组为5/32(16%)。对于成功拔管的患者(n = 54),骶管活性治疗显著延迟了3期患者术后需要急救吗啡的时间(P = 0.02),但在2期患者中未显示出延迟(P = 0.189)(采用对数秩检验的Kaplan-Meier生存分析)。骶管活性治疗使术后12小时吗啡需求量的减少未达到显著水平(P = 0.085),但2期患者的吗啡需求量显著高于3期患者(P < 0.001)(n = 50名已拔管患者的双向方差分析)。
大剂量骶管注射吗啡联合布比卡因延迟了3期患者需要急救吗啡镇痛的时间。所有2期患者均需要早期急救吗啡,且术后12小时吗啡需求量显著高于3期患者。无论镇痛方案如何,大多数2期和3期SV患者早期拔管是可行的。该研究评估拔管失败率差异的效能不足。